GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain
Keywords: 
Breast cancer
Pandemic
COVID-19
SARS-CoV-2
Expert recommendations
Issue Date: 
2020
ISSN: 
1083-7159
Note: 
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Citation: 
Martín, M. (Miguel); Guerrero-Zotano, A. (Angel); Montero, Á. (Ángel); et al. "GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain". The Oncologist. 25 (9), 2020, e1339 - e1345
Abstract
Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARSCoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations are mainly based on expert opinion, medical organizations’ and societies’ recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing.

Files in This Item:
Thumbnail
File
oncolo_25_9_e1339.pdf
Description
Size
441.22 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.